MAP2K7 and Papillary Craniopharyngioma: Recently, Brastianos et al. completed the first non-randomized clinical trial studying safety and efficacy of combined BRAF and MEK inhibition in histopathological and genome sequencing proven V600E mutated papillary craniopharyngioma.